Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Extensively Drug-Resistant Tuberculosis"" wg kryterium: Temat


Tytuł :
The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis.
Autorzy :
Mitnick CD; Department of Global Health and Social Medicine Harvard Medical School Boston, Massachusetts.; Partners In Health Boston, Massachusetts.
Furin JJ; Department of Global Health and Social Medicine Harvard Medical School Boston, Massachusetts.
Hewison C; Médecins sans Frontières Paris, France.
Pokaż więcej
Źródło :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2021 Sep 15; Vol. 204 (6), pp. 629-631.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/diagnosis
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Antitubercular Agents/therapeutic use ; Humans
Opinia redakcyjna
Tytuł :
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Autorzy :
Roelens M; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Battista Migliori G; Istituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico, Tradate, Italy.
Rozanova L; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Estill J; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Institute of Mathematical Statistics and Actuarial Science, University of Bern, Bern, Switzerland.
Campbell JR; McGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Cegielski JP; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Tiberi S; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.; Division of Infection, Royal London Hospital, Barts Health National Health Service Trust, London, United Kingdom.
Palmero D; Hospital F. J. Muñiz, Buenos Aires, Argentina.
Fox GJ; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Guglielmetti L; Équipe 13, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Unité 1135, Institut National de la Santé et de la Recherche Médicale, Paris, France.; Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Groupe Hospitalier Universitaire Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sotgiu G; Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Brust JCM; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Bang D; Statens Serum Institut, Copenhagen, Denmark.; Department of Clinical Microbiology, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.
Lienhardt C; Unité Mixte Internationale TransVIHMI (Université de Montpellier, UMI 233 IRD, U1175 INSERM), Institut de Recherche pour le Développement, Montpellier, France.; Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Lange C; German Center for Infection Research Clinical Tuberculosis Center, Research Center Borstel, Borstel, Germany.; Department of Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.; Global Tuberculosis Program, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas; and.
Menzies D; McGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada.; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Keiser O; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Raviglione M; Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy.
Pokaż więcej
Źródło :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2021 Sep 15; Vol. 204 (6), pp. 713-722.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents/*therapeutic use
Extensively Drug-Resistant Tuberculosis/*diagnosis
Extensively Drug-Resistant Tuberculosis/*drug therapy
Adult ; Aged ; Databases, Factual ; Diarylquinolines/therapeutic use ; Drug Administration Schedule ; Drug Resistance, Multiple, Bacterial ; Drug Therapy, Combination ; Extensively Drug-Resistant Tuberculosis/microbiology ; Female ; Fluoroquinolones/therapeutic use ; Humans ; Isoniazid/therapeutic use ; Linezolid/therapeutic use ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Rifampin/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Impact of the revised definition of extensively drug-resistant tuberculosis.
Autorzy :
Veziris N; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Département de Bactériologie, Hôpital Saint-Antoine, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France .
Bonnet I; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Morel F; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Guglielmetti L; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Maitre T; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Sorbonne Université, Paris, France.
Fournier Le Ray L; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Sorbonne Université, Paris, France.
Sougakoff W; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Robert J; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Aubry A; Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Laboratoire de Bactériologie-Hygiène, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, APHP, Sorbonne Université, Sorbonne Université, Paris, France.
Pokaż więcej
Corporate Authors :
CNR MyRMA
Members of the CNR-MyRMA (French National Reference Center for Mycobacteria
Źródło :
The European respiratory journal [Eur Respir J] 2021 Aug 19; Vol. 58 (2). Date of Electronic Publication: 2021 Aug 19 (Print Publication: 2021).
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/diagnosis
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/therapeutic use ; Humans ; Microbial Sensitivity Tests
Raport
Tytuł :
Experiences and needs of patients with MDR/XDR-TB: a qualitative study among Saharia tribe in Madhya Pradesh, Central India.
Autorzy :
Nigam S; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Sharma RK; ICMR- National Institute of Medical Statistics, New Delhi, Delhi, India.
Yadav R; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Rao VG; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Mishra P; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Lingala MA; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Bhat J; Division of Communicable Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India .
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2021 Aug 12; Vol. 11 (8), pp. e044698. Date of Electronic Publication: 2021 Aug 12.
Typ publikacji :
Journal Article
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*
Tuberculosis, Multidrug-Resistant*
Tuberculosis, Pulmonary*
Antitubercular Agents/therapeutic use ; Humans ; India/epidemiology ; Population Groups ; Prevalence
Czasopismo naukowe
Tytuł :
Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
Autorzy :
Alagna R; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cabibbe AM; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Miotto P; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Saluzzo F; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Köser CU; Dept of Genetics, University of Cambridge, Cambridge, UK.
Niemann S; Molecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Borstel, Germany.; German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Germany.
Gagneux S; Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Rodrigues C; Dept of Microbiology, P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India.
Rancoita PVM; University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.
Cirillo DM; IRCCS San Raffaele Scientific Institute, Milan, Italy .
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2021 Jul 01; Vol. 58 (1). Date of Electronic Publication: 2021 Jul 01 (Print Publication: 2021).
Typ publikacji :
Letter; Comment
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/diagnosis
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/therapeutic use ; Humans ; World Health Organization
Opinia redakcyjna
Tytuł :
Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
Autorzy :
Riccardi N; StopTB Italia Onlus, Milan, Italy, Department of Infectious, Tropical Diseases and Microbiology, Istituto di Ricovero e Cura a Carattere Scientific (IRCCS) Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Saderi L; StopTB Italia Onlus, Milan, Italy, Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Borroni E; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Tagliani E; IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cirillo DM; StopTB Italia Onlus, Milan, Italy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marchese V; WHO Collaborating Centre for TB/HIV Collaborative Activities and for the TB Elimination Strategy, University Division of Infectious and Tropical Diseases, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, Italy.
Matteelli A; WHO Collaborating Centre for TB/HIV Collaborative Activities and for the TB Elimination Strategy, University Division of Infectious and Tropical Diseases, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, Italy.
Piana A; Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Castellotti P; StopTB Italia Onlus, Milan, Italy, Regional TB Reference Centre, Istituto Villa Marelli, Niguarda Hospital, Milan, Italy.
Ferrarese M; StopTB Italia Onlus, Milan, Italy, Regional TB Reference Centre, Istituto Villa Marelli, Niguarda Hospital, Milan, Italy.
Gualano G; StopTB Italia Onlus, Milan, Italy, Respiratory Infectious Diseases Unit, Italy.
Palmieri F; Respiratory Infectious Diseases Unit, Italy.
Girardi E; Clinical Epidemiology Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.
Codecasa L; StopTB Italia Onlus, Milan, Italy, Regional TB Reference Centre, Istituto Villa Marelli, Niguarda Hospital, Milan, Italy.
Sotgiu G; StopTB Italia Onlus, Milan, Italy, Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Pokaż więcej
Źródło :
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2021 May 01; Vol. 25 (5), pp. 395-399.
Typ publikacji :
Journal Article
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Antitubercular Agents/therapeutic use ; Female ; Humans ; Italy/epidemiology ; Male ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.
Autorzy :
van de Berg SEJ; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Pelzer PT; KNCV Tuberculosis foundation, The Hague, The Netherlands. .
van der Land AJ; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Abdrakhmanova E; National TB Program Kyrgyzstan, Bishkek, Kyrgyzstan.
Ozi AM; National Tuberculosis and Leprosy control Program Nigeria, Mabushi, Nigeria.
Arias M; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Cook-Scalise S; TB Alliance, New York, USA.
Dravniece G; KNCV Tuberculosis foundation, The Hague, The Netherlands.; PATH, Kyiv, Ukraine.
Gebhard A; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Juneja S; TB Alliance, New York, USA.
Handayani R; National TB Program Indonesia, Jakarta, Indonesia.
Kappel D; TB Alliance, New York, USA.
Kimerling M; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Koppelaar I; KNCV Tuberculosis foundation, The Hague, The Netherlands.
Malhotra S; TB Alliance, New York, USA.
Myrzaliev B; KNCV country office Kyrgyzstan, Bishkek, Kyrgyzstan.
Nsa B; KNCV country office Nigeria, Abuja, Nigeria.
Sugiharto J; Yayasan KNCV Indonesia, Jakarta, Indonesia.
Engel N; Maastricht University, Maastricht, The Netherlands.
Mulder C; KNCV Tuberculosis foundation, The Hague, The Netherlands.; Amsterdam Institute for Global Health and Development, Amsterdam University Medical Center, Amsterdam, The Netherlands.
van den Hof S; KNCV Tuberculosis foundation, The Hague, The Netherlands.; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Pokaż więcej
Źródło :
BMC public health [BMC Public Health] 2021 Jul 16; Vol. 21 (1), pp. 1404. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/therapeutic use ; Feasibility Studies ; Humans ; Indonesia ; Kyrgyzstan ; Nigeria
Czasopismo naukowe
Tytuł :
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Autorzy :
Oelofse S; Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
Esmail A; Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
Diacon AH; Task Applied Science and Stellenbosch University, Cape Town, South Africa.
Conradie F; Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, Sizwe Tropical Disease Hospital, Sandringham, South Africa.
Olayanju O; Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa.
Ngubane N; Task Applied Science and Stellenbosch University, Cape Town, South Africa, King DinuZulu Hospital Complex, Durban, South Africa.
Howell P; Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, Sizwe Tropical Disease Hospital, Sandringham, South Africa.
Everitt D; TB Alliance, New York, NY, USA.
Crook AM; Institute of Clinical Trials and Methodology, University College London, London, UK.
Mendel CM; TB Alliance, New York, NY, USA.
Wills GH; Institute of Clinical Trials and Methodology, University College London, London, UK.
Olugbosi M; TB Alliance, Pretoria, South Africa.
Del Parigi A; TB Alliance, New York, NY, USA.
Sun E; TB Alliance, New York, NY, USA.
Calatroni A; Rho Federal Systems Division, Inc., Durham, NC, USA.
Spigelman M; TB Alliance, New York, NY, USA.
Dheda K; Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town (UCT), Cape Town, South Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Pokaż więcej
Źródło :
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2021 Jun 01; Vol. 25 (6), pp. 453-460.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/therapeutic use ; Diarylquinolines/therapeutic use ; Humans ; Linezolid/therapeutic use ; Nitroimidazoles ; Prospective Studies
Czasopismo naukowe
Tytuł :
Bedaquiline: Current status and future perspectives.
Autorzy :
Khoshnood S; Clinical MicrobiologyResearch Center, Ilam University of Medical Sciences, Ilam, Iran.
Goudarzi M; Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Taki E; Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Darbandi A; Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Kouhsari E; Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Heidary M; Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran; Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran. Electronic address: .
Motahar M; Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Moradi M; Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Bazyar H; Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Pokaż więcej
Źródło :
Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2021 Jun; Vol. 25, pp. 48-59. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Diarylquinolines/therapeutic use ; Humans
Czasopismo naukowe
Tytuł :
Multi-drug resistant tuberculosis, ten years later.
Autorzy :
Caminero Luna JA; Unidad de Tuberculosis y Micobacteriosis, Servicio de Neumología, Hospital General de Gran Canaria «Dr. Negrin», Las Palmas de Gran CanariaEspaña. Electronic address: .
Pérez Mendoza G; Unidad de Tuberculosis y Micobacteriosis, Servicio de Neumología, Hospital General de Gran Canaria «Dr. Negrin», Las Palmas de Gran CanariaEspaña.
Rodríguez de Castro F; Unidad de Tuberculosis y Micobacteriosis, Servicio de Neumología, Hospital General de Gran Canaria «Dr. Negrin», Las Palmas de Gran CanariaEspaña.
Pokaż więcej
Transliterated Title :
Tuberculosis multirresistentediez años después.
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 Apr 23; Vol. 156 (8), pp. 393-401. Date of Electronic Publication: 2021 Jan 31.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Antitubercular Agents/therapeutic use ; Humans ; Rifampin/therapeutic use
Czasopismo naukowe
Tytuł :
Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.
Autorzy :
Sharma A; Department of Biophysics, Panjab University, Chandigarh 160014, India.; UIPS, Panjab University, Chandigarh 160014, India.
De Rosa M; Drug Discovery Unit, Ri.MED Foundation, Palermo 90133, Italy.
Singla N; Department of Biophysics, Panjab University, Chandigarh 160014, India.
Singh G; UIPS, Panjab University, Chandigarh 160014, India.
Barnwal RP; Department of Biophysics, Panjab University, Chandigarh 160014, India.
Pandey A; Department of Chemistry, Panjab University, Chandigarh 160014, India.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 Apr 22; Vol. 64 (8), pp. 4359-4395. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antitubercular Agents/*chemistry
Extensively Drug-Resistant Tuberculosis/*pathology
Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Ciprofloxacin/chemistry ; Ciprofloxacin/pharmacology ; Ciprofloxacin/therapeutic use ; Disease Progression ; Drug Carriers/chemistry ; Drug Evaluation, Preclinical ; Drug Resistance, Bacterial/genetics ; Extensively Drug-Resistant Tuberculosis/drug therapy ; Extensively Drug-Resistant Tuberculosis/immunology ; Humans ; Microbial Sensitivity Tests ; Mycobacterium tuberculosis/drug effects ; Streptomycin/chemistry ; Streptomycin/pharmacology ; Streptomycin/therapeutic use ; Structure-Activity Relationship ; Thiophenes/chemistry ; Thiophenes/pharmacology ; Thiophenes/therapeutic use ; Toll-Like Receptors/metabolism
Czasopismo naukowe
Tytuł :
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
Autorzy :
Viney K; Global TB Programme, World Health Organization, Geneva, Switzerland.
Linh NN; Global TB Programme, World Health Organization, Geneva, Switzerland.
Gegia M; Global TB Programme, World Health Organization, Geneva, Switzerland.
Zignol M; Global TB Programme, World Health Organization, Geneva, Switzerland.
Glaziou P; Global TB Programme, World Health Organization, Geneva, Switzerland.
Ismail N; Global TB Programme, World Health Organization, Geneva, Switzerland.
Kasaeva T; Global TB Programme, World Health Organization, Geneva, Switzerland.
Mirzayev F; Global TB Programme, World Health Organization, Geneva, Switzerland.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2021 Apr 08; Vol. 57 (4). Date of Electronic Publication: 2021 Apr 08 (Print Publication: 2021).
Typ publikacji :
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/diagnosis
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Antitubercular Agents/therapeutic use ; Humans ; World Health Organization
Raport
Tytuł :
Drug resistant Tuberculosis: A review.
Autorzy :
Khawbung JL; Department of Biotechnology, Assam University, Silchar, 788011, Assam, India.
Nath D; Department of Biotechnology, Assam University, Silchar, 788011, Assam, India.
Chakraborty S; Department of Biotechnology, Assam University, Silchar, 788011, Assam, India. Electronic address: .
Pokaż więcej
Źródło :
Comparative immunology, microbiology and infectious diseases [Comp Immunol Microbiol Infect Dis] 2021 Feb; Vol. 74, pp. 101574. Date of Electronic Publication: 2020 Nov 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Extensively Drug-Resistant Tuberculosis*/veterinary
Mycobacterium tuberculosis*/genetics
Animals ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Disease Outbreaks ; Drug Resistance, Multiple, Bacterial
Czasopismo naukowe
Tytuł :
[Research progress in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis].
Autorzy :
Liu L
Zhang RH
Yang S
Pokaż więcej
Źródło :
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [Zhonghua Jie He He Hu Xi Za Zhi] 2021 Apr 12; Vol. 44 (4), pp. 387-390.
Typ publikacji :
Journal Article
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/therapeutic use ; Drug Resistance, Multiple, Bacterial ; Humans
Czasopismo naukowe
Tytuł :
Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis.
Autorzy :
Martín-García M; Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
Esteban J; Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2021 Apr; Vol. 22 (5), pp. 535-541. Date of Electronic Publication: 2021 Jan 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Diarylquinolines ; Humans
Czasopismo naukowe
Tytuł :
TB management in the European Union/European Economic Area: a multi-centre survey.
Autorzy :
Sotgiu G; Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Rosales-Klintz S; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Centis R; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
D'Ambrosio L; Public Health Consulting Group, Lugano, Switzerland.
Verduin R; Verduin Public Health Consult, Oegstgeest, the Netherlands.
Correia AM; Regional Health Administration of the North, Department of Public Health, Porto, Portugal.
Cirule A; Centre of TB and Lung Diseases, Riga East University Hospital, Riga, Latvia.
Duarte R; National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of Pneumology; Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal.
Gadzheva B; The Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM) Programme, Department of Management of Specialized Donor-Funded Programmes, Ministry of Health, Sofia, Bulgaria.
Gualano G; Respiratory Infectious Diseases Unit, L Spallanzani National Institute for Infectious Diseases, IRCCS, Rome, Italy.
Kunst H; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
Palmieri F; Respiratory Infectious Diseases Unit, L Spallanzani National Institute for Infectious Diseases, IRCCS, Rome, Italy.
Riekstina V; Centre of TB and Lung Diseases, Riga East University Hospital, Riga, Latvia.
Stefanova D; St Sofia University Hospital for Active Treatment of Respiratory Diseases, Sofia, Bulgaria.
Tiberi S; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
van der Werf MJ; European Centre for Disease Prevention and Control, Stockholm, Sweden.
Migliori GB; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
Pokaż więcej
Źródło :
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2021 Feb 01; Vol. 25 (2), pp. 126-133.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Extensively Drug-Resistant Tuberculosis*
Tuberculosis, Multidrug-Resistant*
Europe ; European Union ; Humans ; Reference Standards
Czasopismo naukowe
Tytuł :
Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.
Autorzy :
Sheikh BA; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Bhat BA; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Mehraj U; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Mir W; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Hamadani S; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Mir MA; Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar-190006, India.
Pokaż więcej
Źródło :
Current pharmaceutical biotechnology [Curr Pharm Biotechnol] 2021; Vol. 22 (4), pp. 480-500.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antitubercular Agents/*therapeutic use
Extensively Drug-Resistant Tuberculosis/*drug therapy
Tuberculosis, Multidrug-Resistant/*drug therapy
Animals ; Extensively Drug-Resistant Tuberculosis/genetics ; Extensively Drug-Resistant Tuberculosis/microbiology ; Humans ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/genetics ; Tuberculosis, Multidrug-Resistant/genetics ; Tuberculosis, Multidrug-Resistant/microbiology
Czasopismo naukowe
Tytuł :
A systemic approach to explore the mechanisms of drug resistance and altered signaling cascades in extensively drug-resistant tuberculosis.
Autorzy :
Udhaya Kumar S; School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Saleem A; School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Thirumal Kumar D; Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.
Anu Preethi V; School of Computer Science and Engineering, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Younes S; Translational Research Institute, Women's Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar.
Zayed H; Department of Biomedical Sciences, College of Health and Sciences, QU Health, Qatar University, Doha, Qatar.
Tayubi IA; Faculty of Computing and Information Technology, King Abdul-Aziz University, Rabigh, Saudi Arabia.
George Priya Doss C; School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India. Electronic address: .
Pokaż więcej
Źródło :
Advances in protein chemistry and structural biology [Adv Protein Chem Struct Biol] 2021; Vol. 127, pp. 343-364. Date of Electronic Publication: 2021 Mar 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bacterial Proteins*/genetics
Bacterial Proteins*/metabolism
Extensively Drug-Resistant Tuberculosis*/genetics
Extensively Drug-Resistant Tuberculosis*/metabolism
Gene Expression Regulation, Bacterial*
Mycobacterium tuberculosis*
Systems Biology*
Drug Resistance, Bacterial/*genetics
Humans
Czasopismo naukowe
Tytuł :
Genomic evidence supporting the clonal expansion of extensively drug-resistant tuberculosis bacteria belonging to a rare proto - Beijing genotype.
Autorzy :
Srilohasin P; Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Drug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.
Prammananan T; Drug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.; National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
Faksri K; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
Phelan JE; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Suriyaphol P; Division of Bioinformatics and Data Management for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Research Group and Research Network Division, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Kamolwat P; Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Smithtikarn S; Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Disratthakit A; Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Regmi SM; Department of Microbiology, Gandaki Medical College Teaching Hospital, Pokhara, Nepal.
Leechawengwongs M; Drug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.; Vichaiyut Hospital, Bangkok, Thailand.
Twee-Hee Ong R; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Teo YY; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Tongsima S; National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.; National Biobank of Thailand, National Science and Technology Development Agency, Pathum Thani, Thailand.
Clark TG; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Chaiprasert A; Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Drug Resistant Tuberculosis Research Fund, Siriraj Foundation, Bangkok, Thailand.
Pokaż więcej
Źródło :
Emerging microbes & infections [Emerg Microbes Infect] 2020 Dec; Vol. 9 (1), pp. 2632-2641.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Bacterial Proteins/*genetics
Extensively Drug-Resistant Tuberculosis/*epidemiology
Mycobacterium tuberculosis/*classification
Beijing ; Clonal Evolution ; Extensively Drug-Resistant Tuberculosis/microbiology ; Genotype ; Humans ; Mycobacterium tuberculosis/genetics ; Mycobacterium tuberculosis/isolation & purification ; Mycobacterium tuberculosis/pathogenicity ; Phylogeny ; Phylogeography ; Thailand/epidemiology ; Virulence
Czasopismo naukowe
Tytuł :
Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
Autorzy :
Borah P; Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India.
Deb PK; Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, PO Box 1, Amman 19392, Jordan.
Venugopala KN; Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Al-Shar'i NA; Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
Singh V; Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch, 7701, South Africa.
Deka S; Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-26, Assam, India.
Srivastava A; Neuroscience and Pain Research Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221 005, India.
Tiwari V; Neuroscience and Pain Research Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221 005, India.
Mailavaram RP; Department of Pharmaceutical Chemistry, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram - 534 202, West Godavari Dist., Andhra Pradesh, India.
Pokaż więcej
Źródło :
Current topics in medicinal chemistry [Curr Top Med Chem] 2021; Vol. 21 (6), pp. 547-570.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antitubercular Agents/*pharmacology
Drug Resistance, Multiple, Bacterial/*drug effects
Extensively Drug-Resistant Tuberculosis/*drug therapy
Mycobacterium tuberculosis/*drug effects
Tuberculosis, Multidrug-Resistant/*drug therapy
Antitubercular Agents/chemistry ; Extensively Drug-Resistant Tuberculosis/pathology ; Humans ; Microbial Sensitivity Tests ; Molecular Structure ; Tuberculosis, Multidrug-Resistant/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies